United Therapeutics Corporation $UTHR Shares Bought by Tredje AP fonden

Tredje AP fonden boosted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 28.7% during the fourth quarter, HoldingsChannel reports. The fund owned 5,561 shares of the biotechnology company’s stock after buying an additional 1,241 shares during the period. Tredje AP fonden’s holdings in United Therapeutics were worth $2,710,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics in the third quarter worth $317,617,000. Baillie Gifford & Co. purchased a new stake in United Therapeutics during the 4th quarter worth about $157,390,000. Balyasny Asset Management L.P. raised its position in United Therapeutics by 863.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after purchasing an additional 136,883 shares in the last quarter. Sofinnova Investments Inc. purchased a new position in shares of United Therapeutics in the 2nd quarter valued at about $34,055,000. Finally, Orbimed Advisors LLC acquired a new position in shares of United Therapeutics during the third quarter worth about $48,167,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $567.04, for a total transaction of $5,386,880.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,972,491.52. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nilda Mesa sold 258 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $581.93, for a total value of $150,137.94. Following the transaction, the director directly owned 5,028 shares in the company, valued at approximately $2,925,944.04. This represents a 4.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 550,413 shares of company stock worth $305,867,937 in the last quarter. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Stock Down 0.0%

Shares of NASDAQ UTHR opened at $566.80 on Wednesday. The stock has a market cap of $24.06 billion, a PE ratio of 20.92, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The business has a 50-day moving average price of $561.48 and a 200 day moving average price of $509.54.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.63 EPS. Sell-side analysts anticipate that United Therapeutics Corporation will post 27.07 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on UTHR. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. HC Wainwright upped their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Finally, Bank of America raised their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.